

Title (en)
HUMAN POLYPEPTIDES CAUSING OR LEADING TO THE KILLING OF CELLS INCLUDING LYMPHOID TUMOR CELLS

Title (de)
HUMANE POLYPEPTIDE WELCHE ZUM ABSTERBEN VON ZELLEN, INSBESONDERE LYMPHOIDER TUMORZELLEN, FÜHREN

Title (fr)
POLYPEPTIDES HUMAINS PROVOQUANT LA MORT DES CELLULES, NOTAMMENT DES CELLULES TUMORALES LYMPHOIDES

Publication
EP 1289551 A1 20030312 (EN)

Application
EP 01935513 A 20010514

Priority
• EP 01935513 A 20010514
• EP 00110065 A 20000512
• US 0115625 W 20010514
• US 23849200 P 20001006

Abstract (en)
[origin: EP1156060A1] The present invention relates to human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells. The invention further relates to nucleic acids encoding the peptides/proteins, methods for the production of the peptides/proteins, methods for killing cells, pharmaceutical, diagnostic and multivalent compositions and kits comprising the peptides/proteins and uses of the peptides/proteins.
<IMAGE>

IPC 1-7
A61K 39/395; A61K 39/44

IPC 8 full level
C07K 16/28 (2006.01); **C12N 15/09** (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61K 39/395** (2006.01); **A61K 39/44** (2006.01); **A61P 1/04** (2006.01); **A61P 1/16** (2006.01); **A61P 1/18** (2006.01); **A61P 3/10** (2006.01); **A61P 5/14** (2006.01); **A61P 13/12** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 21/04** (2006.01); **A61P 25/00** (2006.01); **A61P 35/02** (2006.01); **A61P 37/02** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01); **C12N 1/15** (2006.01); **C12N 1/19** (2006.01); **C12N 1/21** (2006.01); **C12N 5/07** (2010.01); **C12N 5/078** (2010.01); **C12N 5/09** (2010.01); **C12N 5/10** (2006.01); **C12P 21/02** (2006.01); **C12Q 1/02** (2006.01); **G01N 33/53** (2006.01); **A61P 37/00** (2006.01)

CPC (source: EP)
A61P 1/04 (2017.12); **A61P 1/16** (2017.12); **A61P 1/18** (2017.12); **A61P 3/10** (2017.12); **A61P 5/14** (2017.12); **A61P 13/12** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 21/04** (2017.12); **A61P 25/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/00** (2017.12); **A61P 37/02** (2017.12); **A61P 37/06** (2017.12); **A61P 43/00** (2017.12); **C07K 16/28** (2013.01); **C07K 16/2833** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/21** (2013.01); **C07K 2317/31** (2013.01); **C07K 2317/34** (2013.01); **C07K 2317/55** (2013.01); **C07K 2317/565** (2013.01); **C07K 2317/622** (2013.01); **C07K 2317/76** (2013.01)

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated extension state (EPC)
LT LV

DOCDB simple family (publication)
EP 1156060 A1 20011121; EP 1156060 B1 20070627; AT E365749 T1 20070715; AU 2001261602 B2 20060706; AU 2006225244 A1 20061026; AU 6160201 A 20011126; CA 2408360 A1 20011122; CN 1607959 A 20050420; DE 60035337 D1 20070809; DE 60035337 T2 20080228; EP 1289551 A1 20030312; EP 1289551 A4 20090610; HK 1053985 A1 20031114; JP 2004515214 A 20040527; RU 2004121673 A 20060110; WO 0187337 A1 20011122

DOCDB simple family (application)
EP 00110065 A 20000512; AT 00110065 T 20000512; AU 2001261602 A 20010514; AU 2006225244 A 20061005; AU 6160201 A 20010514; CA 2408360 A 20010514; CN 01809346 A 20010514; DE 60035337 T 20000512; EP 01935513 A 20010514; HK 03106349 A 20030905; JP 2001583804 A 20010514; RU 2004121673 A 20040714; US 0115625 W 20010514